NO995843L - Farmasoeytisk preparat omfattende vWF-propeptid - Google Patents

Farmasoeytisk preparat omfattende vWF-propeptid

Info

Publication number
NO995843L
NO995843L NO995843A NO995843A NO995843L NO 995843 L NO995843 L NO 995843L NO 995843 A NO995843 A NO 995843A NO 995843 A NO995843 A NO 995843A NO 995843 L NO995843 L NO 995843L
Authority
NO
Norway
Prior art keywords
pharmaceutical preparation
vwf propeptide
vwf
propeptide
preparation
Prior art date
Application number
NO995843A
Other languages
English (en)
Other versions
NO324064B1 (no
NO995843D0 (no
Inventor
Hans-Peter Schwarz
Katalin Varadi
Peter Turecek
Hendrik Coenraad Hemker
Suzette Lucette Beguin
Original Assignee
Baxter Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Ag filed Critical Baxter Ag
Publication of NO995843D0 publication Critical patent/NO995843D0/no
Publication of NO995843L publication Critical patent/NO995843L/no
Publication of NO324064B1 publication Critical patent/NO324064B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO19995843A 1997-05-28 1999-11-29 Farmasoytisk preparat omfattende vWF-propeptid samt fremgangsmate for fremstilling og anvendelse derav NO324064B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0091797A AT405485B (de) 1997-05-28 1997-05-28 Eine das vwf-propeptid enthaltende pharmazeutische präparation
PCT/EP1998/003090 WO1998053848A1 (en) 1997-05-28 1998-05-26 PHARMACEUTICAL PREPARATION COMPRISING vWF PROPEPTIDE

Publications (3)

Publication Number Publication Date
NO995843D0 NO995843D0 (no) 1999-11-29
NO995843L true NO995843L (no) 2000-01-27
NO324064B1 NO324064B1 (no) 2007-08-06

Family

ID=3502803

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19995843A NO324064B1 (no) 1997-05-28 1999-11-29 Farmasoytisk preparat omfattende vWF-propeptid samt fremgangsmate for fremstilling og anvendelse derav

Country Status (10)

Country Link
US (2) US7005502B1 (no)
EP (1) EP0977584B1 (no)
JP (1) JP4335978B2 (no)
AT (2) AT405485B (no)
AU (1) AU744643B2 (no)
CA (1) CA2288737A1 (no)
DE (1) DE69802918T2 (no)
ES (1) ES2168766T3 (no)
NO (1) NO324064B1 (no)
WO (1) WO1998053848A1 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7033994B2 (en) 1999-12-24 2006-04-25 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Medicinal compositions for preventing and treating hemorrhagic diseases associating thrombopathy
JP4663837B2 (ja) * 1999-12-24 2011-04-06 一般財団法人化学及血清療法研究所 第▲ｖｉｉｉ▼因子を主成分とする血小板減少に伴う出血疾患の予防・治療用医薬組成物
EP1835938B1 (en) 2004-12-27 2013-08-07 Baxter International Inc. Polymer-von willebrand factor-conjugates
US7683158B2 (en) 2006-03-31 2010-03-23 Baxter International Inc. Pegylated factor VIII
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
EP3936116A1 (en) * 2007-12-28 2022-01-12 Takeda Pharmaceutical Company Limited Rrecombinant vwf containing formulations
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
ES2298096B1 (es) 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
PT2349314E (pt) 2008-10-21 2013-05-28 Baxter Int Formulações de vwf recombinante liofilizado
NZ609908A (en) * 2008-10-27 2014-07-25 Baxter Int Models of thrombotic thrombocytopenic purpura and methods of use thereof
AU2010284116B9 (en) 2009-08-20 2015-03-26 Takeda Pharmaceutical Company Limited Purification of VWF for increased removal of non-lipid enveloped viruses
US20110150843A1 (en) * 2009-10-30 2011-06-23 National Institute Of Immunology Method for the therapeutic correction of hemophilia a by transplanting bone marrow cells
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
WO2017055072A1 (en) 2015-10-02 2017-04-06 Asml Netherlands B.V. Metrology method and apparatus, computer program and lithographic system
BR112020000322A2 (pt) 2017-07-07 2020-07-14 Baxalta Incorporated uso de fator de von willebrand recombinante (rvwf)
PT3648788T (pt) 2017-07-07 2024-08-23 Takeda Pharmaceuticals Co Tratamento de hemorragia gastrointestinal em pacientes com doença de von willebrand grave por administração de fvw recombinante
AU2019240135B2 (en) 2018-03-21 2024-10-03 Takeda Pharmaceutical Company Limited Separation of VWF and VWF propeptide by chromatographic methods
SG11202108325YA (en) 2019-02-01 2021-08-30 Takeda Pharmaceuticals Co Methods of prophylactic treatment using recombinant vwf (rvwf)
JP2022547556A (ja) 2019-09-11 2022-11-14 武田薬品工業株式会社 フォン・ヴィレブランド因子と補体ｃ１ｑの複合体に関連する治療法
JP2023514541A (ja) 2020-02-04 2023-04-06 武田薬品工業株式会社 組換えｖｗｆの投与による重症のフォンヴィレブランド病患者における過多月経の治療

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT350726B (de) 1976-08-30 1979-06-11 Immuno Ag Verfahren zur herstellung einer blut- gerinnungsfoerdernden praeperation aus menschlichem blutplasma
AT368883B (de) 1980-07-22 1982-11-25 Immuno Ag Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
AT378005B (de) 1983-08-20 1985-06-10 Linde Ag Verfahren zum desoxidieren von metallschmelzen
AT389815B (de) 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
AT390560B (de) 1986-05-30 1990-05-25 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
US5849536A (en) * 1990-03-02 1998-12-15 Bio-Technology General Corp. Cloning and production of human von willebrand factor GPIb binding domain polypeptides and methods of using same
FR2673632A1 (fr) * 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
AT402891B (de) 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
AT398079B (de) 1991-11-04 1994-09-26 Immuno Ag Präparation mit thrombinaktivität sowie verfahren zu ihrer herstellung
WO1994013329A1 (de) 1992-12-16 1994-06-23 Immuno Aktiengesellschaft Verfahren zur herstellung eines virussicheren biologischen präparates
AT402788B (de) 1993-08-03 1997-08-25 Immuno Ag Virussichere blutgerinnungsfaktor xiii-präparation
JPH07330797A (ja) 1994-05-31 1995-12-19 Sumitomo Metal Ind Ltd 新規細胞接着活性ペプチド
DE4437544A1 (de) * 1994-10-20 1996-04-25 Behringwerke Ag Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
AT404359B (de) 1996-04-29 1998-11-25 Immuno Ag Gereinigte multimerase
AT404554B (de) 1996-04-29 1998-12-28 Immuno Ag Pharmazeutische präparation
US6068838A (en) 1996-04-29 2000-05-30 Baxter Aktiengesellschaft Purified multimerase

Also Published As

Publication number Publication date
NO324064B1 (no) 2007-08-06
EP0977584B1 (en) 2001-12-12
DE69802918T2 (de) 2003-04-10
US7005502B1 (en) 2006-02-28
JP4335978B2 (ja) 2009-09-30
AU7915698A (en) 1998-12-30
WO1998053848A1 (en) 1998-12-03
NO995843D0 (no) 1999-11-29
EP0977584A1 (en) 2000-02-09
AU744643B2 (en) 2002-02-28
US7557188B2 (en) 2009-07-07
DE69802918D1 (de) 2002-01-24
AT405485B (de) 1999-08-25
ES2168766T3 (es) 2002-06-16
ATA91797A (de) 1999-01-15
ATE210455T1 (de) 2001-12-15
US20060003921A1 (en) 2006-01-05
JP2001527579A (ja) 2001-12-25
CA2288737A1 (en) 1998-12-03

Similar Documents

Publication Publication Date Title
NO995843L (no) Farmasoeytisk preparat omfattende vWF-propeptid
ATE262336T1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
ATE207349T1 (de) Thip zur behandlung von schlafstörungen
PT841928E (pt) Formulacao de libertacao prolongada de d-trep-metilfenidato
NO179531C (no) Fremgangsmåte for brönnbehandling
EA200000358A1 (ru) Способ получения диарилпиридинов, полезных в качестве ингибиторов cox-2
PT865294E (pt) Processo para a reducao ou a manutencao de niveis reduzidos de lipidos no sangue utilizando composicoes de proteina ob
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
EA199700170A1 (ru) Способ получения некоторых азациклогексапетидов
ATA76995A (de) Stabiles präparat zur behandlung von blutgerinnungsstörungen
ATE493978T1 (de) Behandlung von autoimmunerkrankungen
ATE202483T1 (de) Immuntolerante prothrombinkomplex-präparation
ATE239474T1 (de) Verwendung von levobupivacain
PT93959A (pt) Processo para a preparacao de derivados de sacarina uteis como inibidores proteoliticos de enzima
EA199800866A1 (ru) Способ снятия боли
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
EA199800864A1 (ru) Способ лечения при боли, вызванной мигренью
BR0012921A (pt) Compostos calcilìticos
DE69736180D1 (de) Behandlung von manischen erkrankungen
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
NO995132D0 (no) Fremgangsmåte for reduksjon av fibrinogen
NO984198L (no) FremgangsmÕte for behandling av aggresjon
ATA159597A (de) Präparat zur behandlung von blutgerinnungsstörungen
EA199800818A1 (ru) Способ лечения бессонницы
UA43389C2 (uk) Спосіб зниження рівнів кальцію у сироватці

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BAXALTA INCORPORATED, CH

MK1K Patent expired